Printer Friendly

UNIVERSITY OF MINNESOTA, LECTEC AGREE TO DEVELOP NICOTINE-FREE SMOKING CESSATION TREATMENT

 UNIVERSITY OF MINNESOTA, LECTEC AGREE TO DEVELOP NICOTINE-FREE
 SMOKING CESSATION TREATMENT
 MINNEAPOLIS, Jan. 8, /PRNewswire/-- LecTec Corporation (NASDAQ: LETC) and the University of Minnesota Office of Research and Technology Transfer today announced the signing of an agreement to develop new smoking cessation products. The products, an oral dosage form and a transdermal drug delivery patch, will contain a novel nicotine-free drug. Preliminary research indicates that the nicotine-free system is less toxic and potentially safer than nicotine-containing smoking cessation products.
 Under terms of the agreement, LecTec, a medical products developer and manufacturer of electrodes, tapes and transdermal systems, will provide $160,000 for the first phase of research and development leading to commercializion of the smoking cessation technology. Initial research by University of Minnesota scientists led by Dr. Dorothy Hatsukami, associate professor of psychiatry, in collaboration with the National Institute on Drug Abuse, has demonstrated the potential effectiveness of the nicotine-free system. Dr. Hatsukami, a well-known researcher of tobacco dependence, is the present director of the Tobacco Research Laboratory at the University of Minnesota Medical School.
 The University of Minnesota Office of Research and Technology Transfer is responsible for building partnerships with industry to commercialize technologies developed by the University of Minnesota. LecTec Corporation is a manufacturer and marketer of a variety of cardiac electrodes, medical tapes and transdermal drug delivery systems. LecTec is traded on NASDAQ under the symbol LECT.
 -0- 1/08/92
 /CONTACT: Jan Peter Jachimowicz of LecTec, 612-933-2291/
 (LECT) CO: LecTec Corporation ST: Minnesota IN: MTC SU:


LB -- MN008 -- 7673 01/08/92 10:12 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:259
Previous Article:FORD DIVISION ACHIEVES THIRD CONSECUTIVE YEAR OF SALES LEADERSHIP
Next Article:WESTINGHOUSE WON'T SEEK NEW DOE CONTRACT AT FERNALD
Topics:


Related Articles
LECTEC BOARD INTENSIFIES FUNDING FOR TRANSDERMAL PATCH DEVELOPMENT; TO TREAT SMOKERS, CANCER PATIENTS, OTHERS
LECTEC SMOKING CESSATION PATCH DEVELOPMENT PROGRESSES; PATENT PENDING
LECTEC ANNOUNCES FIRST STOCK DIVIDEND IN COMPANY HISTORY; CITES CONFIDENCE FOR THE FUTURE AND BUSINESS EXPANSION
LECTEC AND UNIVERSITY OF MINNESOTA PURSUE SAFER ALTERNATIVE TO NICOTINE FOR SMOKING CESSATION PATCHES
LECTEC RESPONDS TO FDA ADVISORY PANEL INVESTIGATING REPORTS OF ADVERSE REACTIONS OF NICOTINE PATCHES
'PHYSICIAN CHALLENGE PROGRAM' LAUNCHED TO ASSIST PEOPLE WHO WANT TO QUIT SMOKING
LEDERLE REBATING ONE-THIRD THE COST OF PROSTEP(R) NICOTINE PATCH THERAPY, AND DONATING 1 MILLION MORE PATCHES TO ASTHO
LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER...
The LifeSign(R) Stop Smoking Computer: Still the Only Drug-Free, Scientifically Proven Program Today
The LifeSign(R) Stop Smoking Computer: Still the Only Drug-Free, Scientifically Proven Program Today

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters